A new article published in European Neuropsychopharmacology provides a critical assessment of what psychedelic therapies would need in order to be integrated into European healthcare systems. While regulatory approval from the EMA will be necessary, the authors stress that Health Technology Assessment (HTA) bodies across Europe will ultimately determine whether these therapies are reimbursed and accessible.

Only days after PAREA called for a European mental health moonshot, the U.S. Advanced Research Projects Agency for Health (ARPA-H) announced a $100 million mental health moonshot aimed at accelerating leading-edge treatments and developing more objective measures in behavioural health. 

Psilocybin Therapy for Psychological Distress in Palliative Care Patients (PsyPal) - the first EU-funded clinical trial of psychedelic therapy - is now underway and actively recruiting participants across its four trial sites in Copenhagen, Groningen, Lisbon and Prague. 

PAREA is pleased to welcome the Women’s Brain Foundation as a new full member. Their membership helps put greater focus on ensuring that sex and gender differences are systematically recognised and addressed across mental health and psychedelic research, policy, and clinical innovation in Europe.

At an event today in Brussels, the Psychedelic Access and Research European Alliance (PAREA) launched its new policy paper, From Lagging to Leading: A Policy Toolkit for Mental Health Innovation “Made in Europe”.

This new initiative aims to strengthen Europe’s competitiveness in biotechnology - a field increasingly recognised as strategic for Europe’s economic sovereignty, innovation leadership, and resilience. The consultation invited stakeholders to identify barriers in the EU’s regulatory and investment environment and propose actions to unlock the next wave of biotech innovation.